<DOC>
	<DOCNO>NCT01774253</DOCNO>
	<brief_summary>The purpose research study evaluate investigational drug ( Vismodegib ) Pontine Glioma grow come back ( reoccurred ) . This study look tumor response study drug , Vismodegib , also look safety tolerability Vismodegib . Vismodegib test multiple adult clinical trial one pediatric trial . Laboratory test pontine glioma suggest drug may effective treat disease .</brief_summary>
	<brief_title>Erivedge ( Vismodegib ) Treatment Pediatric Patients With Refractory Pontine Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>Subjects must radiographically prove diffuse intrinsic pontine glioma confirmation residual disease initial therapy time recurrence/progression confirm MRI brain Subjects must age ≥3 year ≤ 18 year Diffuse intrinsic pontine glioma measurable disease receive radiotherapy either concurrent follow ≤ 2 prior course chemotherapy Measurable disease define : Measurable tumor &gt; 10mm MRI Karnofsky performance status ( PS ) 60100 % ( patient &gt; 16 year age ) OR Lansky PS 60100 % ( patient ≤ 16 year age ) Body surface area &gt; 0.67 m2 ≤ 2.21 m2 Life expectancy least 2 month A negative urine pregnancy test require female participant child bear potential ( ≥13 year age onset menses ) Acceptable liver function define : 1 . Bilirubin ≤ 1.5 time upper limit normal 2 . AST ( SGOT ) , ALT ( SGPT ) Alkaline phosphatase ≤ 2.5 time upper limit normal Creatinine clearance radioisotope GFR ≥ 70 mL/min OR serum creatinine base age follow : 0.8 mg/dL ( patient ≤ 5 year age ) 1.0 mg/dL ( patient 6 10 year age ) 1.2 mg/dL ( patient 11 15 year age ) 1.5 mg/dL ( patient &gt; 15 year age ) Acceptable hematologic status define : 1 . Granulocyte ≥ 1500 cells/mm3 2 . Platelet count ≥ 100,000 ( plt/mm3 ) 3 . Serum albumin ≥ 2.5 g/dL Urinalysis : . No clinically significant abnormality Acceptable coagulation status define : 1 . PT/INR less 1.5 2 . PTT within normal limit Subjects must able swallow retain oral medication Female postpubertal study subject need agree use one effective birth control method treatment 7 ( seven ) month treatment stop . These method include total abstinence ( sex ) , oral contraceptive ( `` pill '' ) , intrauterine device ( IUD ) , levonorgestrol implant ( Norplant ) , medroxyprogesterone acetate injection ( Depoprovera shot ) . Male postpubertal study subject need agree use condom spermicide , even vasectomy , sexual intercourse female partner treat Erivedge capsule 2 month last dose avoid expose embryo fetus Vismodegib . Voluntarily sign date write IRBapproved informed consent parent legal guardian subject Concurrent anticancer therapy ( chemotherapy , radiation therapy , surgery , immunotherapy , hormonal therapy , biologic therapy ) one specify protocol . Patients must discontinue cancer therapy generally 3 week ( 8 week radiotherapy ) prior first dose study medication , well recover toxicity ( ≤ grade 2 except alopecia ) induce previous treatment . Currently receive another investigational medicinal product . Uncontrolled concurrent illness include , limited : 1 . Active , uncontrolled bacterial , viral , fungal infection require systemic therapy 2 . Diarrhea cause ≥ CTCAE grade 2 3 . Psychiatric illness/social situation would compromise patient safety limit compliance study requirement include maintenance compliance/pill diary 4 . Any kind malabsorption syndrome significantly affect gastrointestinal function Pregnant nursing female patient . NOTE : If female patient become pregnant suspect pregnant participate study , stop take study drug immediately inform treat physician immediately . Prior therapy Hedgehog inhibitor Unwillingness inability comply procedure require protocol Serious nonmalignant disease ( e.g. , hydronephrosis , liver failure , condition ) could compromise protocol objective opinion investigator and/or sponsor . History Congestive Heart Failure ( CHF ) ventricular arrhythmia require medication .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DIPG</keyword>
</DOC>